Article info
PDFReview
Genetic testing in motor neurone disease
- Correspondence to Professor Martin R Turner, Nuffield Department of Clinical Neurosciences, Oxford University, Oxford, Oxfordshire, UK; martin.turner{at}ndcn.ox.ac.uk
Citation
Genetic testing in motor neurone disease
Publication history
- Accepted December 5, 2021
- First published January 13, 2022.
Online issue publication
March 18, 2022
Article Versions
- Previous version (18 March 2022).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.
Other content recommended for you
- Comprehensive analysis of the mutation spectrum in 301 German ALS families
- Value of systematic genetic screening of patients with amyotrophic lateral sclerosis
- Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation
- Genetics insight into the amyotrophic lateral sclerosis/frontotemporal dementia spectrum
- Genotype–phenotype correlation of SQSTM1 variants in patients with amyotrophic lateral sclerosis
- CHMP2B mutations are not a common cause of familial or sporadic amyotrophic lateral sclerosis
- Pathophysiological insights into ALS with C9ORF72 expansions
- Genetic testing and reproductive choice in neurological disorders
- Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
- Effect of familial clustering in the genetic screening of 235 French ALS families